GlobalData on MSN4 个月
Amneal files again for FDA approval of first dihydroergotamine autoinjector
Amneal Pharmaceuticals has submitted another new drug application (NDA) for its dihydroergotamine (DHE) prefilled syringe ...
Medscape3 年
The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache
Ergot alkaloids were the first antimigraine drugs available. Dihydroergotamine (DHE) is an ergotamine analog (Figure 3). DHE is administered as a nasal spray form (Migranal®, Valeant ...
来自MSN3 个月
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA
Amneal Pharmaceuticals (NASDAQ:AMRX) has received FDA approval for its generic version of the GLP-1 agonist diabetes drug Byetta and resubmitted its New Drug Application for a prefilled syringe ...
Clinical Pain Advisor16 天
FDA Drug Approval Decisions Expected in April 2025
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.